Drug Safety, Part D Reimbursement Elevate Biotech Venture Capital Risk, Fund Manager Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Increased risks could result in lower valuations for biotech start-ups, Vector Fund Management Managing Director Phillips tells BIO annual meeting, which "makes it very, very hard for entrepreneurs to raise money." VC focus is shifting to less-risky, later-stage development, he says.